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Abstract
Background: Trigeminal neuralgia is characterized by paroxysmal facial pain attacks. Adequate prophylactic
drug therapy is often limited by the lack of efficacy and intolerance due to central nervous system side effects.
Subcutaneous injections of botulinum toxin type A are a promising treatment option for patients with
unsatisfactory response to drug therapy or neurosurgical intervention. Its effects are expected to last for at
least 3 months, so it could be a potential long-term treatment.
This is the study protocol of a prospective, placebo-controlled, double blind clinical trial investigating the add-on
therapy of subcutaneous administration of botulinum toxin type A injections to standard treatment in therapy-
refractory classical trigeminal neuralgia.
Methods and design: BoTN is a prospective, double blind, placebo-controlled trial with a randomized withdrawal
design in which a single blind phase is followed by a double blind phase (see also Methods and design). Eligible
patients with classical trigeminal neuralgia who are otherwise refractory to medical and neurosurgical treatment will
receive subcutaneous injections of botulinum toxin type A into injection sites of the affected trigeminal branch.
In the first phase all patients will receive botulinum toxin type A in a single blinded intervention. Twelve weeks later
therapy responders will be allocated to the verum or placebo (saline) arm in a double blind, randomized manner.
These injections will be performed at the same sites as the first injections.
This trial will be conducted in a tertiary outpatient clinic specialized in the treatment of headache and facial pain.
There will be three investigators performing the injections who are experienced in the treatment of headache and
facial pain and trained in botulinum toxin type A injections.
Discussion: BoTN is designed to assess the efficacy and safety of subcutaneous botulinum toxin type A injections
in addition to standard prophylactic treatment in therapy-refractory trigeminal neuralgia.
Trial registration number: EU Clinical Trials Register: EudraCT-No: 2014-001959-24 https://www.clinicaltrials
register.eu/ctr-search/rest/download/trial/2014-001959-24/DE
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Background
Trigeminal neuralgia (TN) is a chronic disorder charac-
terized by paroxysms of unilateral, electric shock-like
pain in the distribution of one or more branches of the
trigeminal nerve [1].
It is estimated that approximately 4–28.9/100,000 people
worldwide suffer from TN. It affects mainly the older
population and is more common amongst women [2, 3].
The underlying cause of classic TN, as defined by the
ICHD-3 beta (International Classification of Headache Dis-
orders, third edition), is assumed to be neurovascular com-
pression caused by cerebral vessels. In particular the
superior cerebellar artery can locally affect the trigeminal
nerve causing segmental demyelination and consecutively
ephtatic conduction of painful paroxysms [3].
Secondary forms caused by tumor, trauma, multiple
sclerosis or post-herpetic neuralgia exist and are classified
by the ICHD-3 beta as secondary painful trigeminopathies.
Single pain episodes of TN only last for a few seconds.
The therapeutic strategy is prophylactic treatment.
Treatment consists of anticonvulsive drugs such as
carbamazepine (CBZ), oxcarbarzepine (OXC), phenytoin
or gabapentin. Major treatment limitations are lack of
efficacy and, in an older-aged population, intolerability
due to central nervous system side effects. Drug refrac-
tory courses affect many patients [4].
Evidence for the efficacy of interventional procedures
such as gamma-knife surgery, microvascular decompres-
sion and percutaneous Gasserian ganglion intervention
is limited and sensory side effects in the affected trigemi-
nal branches are common [5].
Botulinum neurotoxin type A (BT-A) is a potent neuro-
toxin derived from Clostridium botulinum. It blocks the
release of acetylcholine at the neuromuscular junction and
has also been found to inhibit the release of proinflamma-
tory peptides. In addition BT-A binds to C- fibers. Anal-
gesic efficacy is proven in the treatment of chronic
migraine and its antinociceptive effects on neuropathic
pain have been established in animal models [6].
Subcutaneous injections of BT-A are a non-invasive
treatment option, which is suitable for patients where
drug therapy or neurosurgical intervention have failed.
Its clinical effects on TN have been studied in several
open and one double blind trial [7–12].
This trial will be conducted in a tertiary outpatient clinic
specialized in the treatment of headache and facial pain.
Standard medical treatment
First-line treatment agents in the therapy of TN are CBZ
and OXC [13, 14].
CBZ has proven its efficacy in four randomized con-
trolled trials (RCTs) and is approved for TN [15–18]. It
is estimated that only 50 % of the patients remain long-
term responders. Therapy-limiting side effects are
common. In doses higher than 600 mg/d central nervous
system side effects such as ataxia, fatigue and vertigo are
very common. Auto- induction of metabolic liver en-
zymes can lower plasma CBZ levels and lead to numer-
ous drug interactions.
In terms of efficacy oxcarbazepine is assumed to be
comparable to CBZ but with a more favorable risk pro-
file. Due to the lack of sufficient clinical data the evi-
dence for its efficacy is limited and it can only be
prescribed off-label. Under therapy, regular screening for
hyponatremia is necessary [19, 20].
Second-line agents are the GABA-B-receptor-agonist
baclofen and other anticonvulsive drugs such as pheny-
toin, gabapentin, lamotrigine, levetiracetam, pregabalin,
topiramate, valproic acid with either insufficient clinical
data or a less favorable risk profile [21–32].
All the aforementioned substances and combinations
of substances can be taken for the duration of the clin-
ical trial as long as the dosage remains unchanged.
Neurosurgical procedures
Neurosurgical procedures are considered alternative
treatment options for patients with drug refractory
courses:
 Microvascular decompression (Janetta procedure) is
estimated to have a response rate of 68 % after ten
years and is preferred over neuroablative procedures
because trigeminal function will be preserved [33]
 Percutaneous ablative procedures such as
thermoablation of the Gasserian ganglion is
estimated to have a 5-year response rate of 50 %
and moderate to severe sensory side effects such
as trigeminal hypoesthesia, or anesthesia dolorosa
[34–36]
 Radiosurgical treatment with a gamma-knife has a
lower response rate (41–45 % after 5 years) with a
more favorable risk profile (sensory impairment in
7.7–49 %) [37]
Previous studies of BT-A in trigeminal neuralgia
The efficacy of BT-A in classical TN has been investi-
gated in several open-label studies and one RCT [7–12].
There were considerable variations in dosage (6–100 U
BT-A per intervention) and the number/localization of
injection sites (between 2 and 15).
Wu et al. conducted the sole RCT [7]: 42 patients
were allocated to either intradermal and optionally, if
the second trigeminal branch was affected, submucosal
injection of 75 U BT-A at 15 injection points in the area
where the patient experienced pain. A response rate of
68 %, defined as > 50 % visual analogue scale (VAS) score
reduction (as compared to 15 % in the placebo group)
has been reported after 12 weeks.
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Hu et al. reviewed the previous studies and rated
the current evidence grade Ib. Further controlled clin-
ical trials were recommended. Overall response rates,
defined a > 50 % reduction in pain frequency or VAS
scores were higher than 60 % [38].
Methods and design
Study design/general structure
The study design is prospective, randomized, placebo-
controlled and double blind (Table 1). A randomized
withdrawal design was chosen, which means that all
patients who respond positively to the first treatment
intervention will consecutively be randomized to con-
tinuing the intervention or receiving placebo. This
study design is useful in clinical trials with only a
small number of patients in order to achieve the ne-
cessary statistical power. Since all patients will at least
once receive verum injections a lower dropout rate
can be expected as compared to a study in parallel
group design.
The study consists of three phases: baseline phase, sin-
gle blind phase and double blind phase. Study duration
for a single patient will be, depending on therapy re-
sponse, between 5 and 25 weeks.
During the baseline phase (week −1) TN attack fre-
quency and pain intensity scores (numeric rating scale,
NRS) will be assessed with a specific diary. Patients are re-
quired to keep their concomitant TN medication (see also
“concomitant medication”) unchanged. Patients with an
average frequency of more than three daily paroxysms will
enter the open-label phase of the trial.
Estimated timeline
Recruitment will begin in November 2014 and will end
in July 2016.
Intervention
During the single blind phase (weeks 1–12) all eligible
patients will receive BT-A injections in accordance to
the injection scheme given below. After week 4 non-
responders to treatment will finish the study early.
Frequency reduction of less than 30 % as compared to
baseline phase will be considered a non-response to BT-A.
Table 1 Visit schedule and methods
First part: single blind Second part: double blind, randomized
Visit schedule and methods V-1 (Screening,
8 days before V0)
V0 = open-label
verum injection
V1 (28 ± 3
days after V0)
V2 = randomized, doubleblind
intervention (84 ± 3 days after V0)
V3 (28 ± 2
days after V2)






X X X X X X
SF-12 Questionnaire assessing
life quality
X X X X X X
ADS Questionnaire assessing
depression
X X X X X X
HIT-6 Questionnaire assessing
pain severity
X X X X X X
Neurological examination X X X X X
Medical examination X X X X X
Blood tests X
Pain-evoked potentials X X X X X
Randomization X
BT-A/Placebo injection X (verum) X (verum/placebo)








X X X X X
Pseudonymization Patients are assigned to a screening number Screening numbers are assigned to randomization list
ADS Allgemeine Depressionsskala: General Depression Scale, HIT-6 Headache Impact Test-6, SF-12 12-item short form questionnaire, TN trigeminal neuralgia
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Double blind phase (weeks 13–24): therapy responders
will be randomized to BT-A injections or placebo injec-
tion (saline) at the same injection sites. Allocation to the
verum/placebo arm is double blind: the BT-A will be dis-
solved in saline in a 0.5 ml/1 ml syringe and 5 U will be
injected near to the nerve exits of the affected trigeminal
branches (Figs. 1 and 2).
Primary outcome parameter
Primary outcome parameter is the average number of
TN attacks within the fourth week after double blind
intervention in V2.
Secondary outcome parameters
1. Change in average TN attack frequency in the fourth
week after BT-A/placebo injection in V2 (= week 16)
as compared to the last 7 days before V0 and V2.
2. Change in average TN attack frequency in the 2nd,
6th, 8th and 12th weeks after V2 as compared to the
last 7 days before V0 and V2.
3. Average pain intensity scores (measured on an 11-point
NRS) in the 2nd, 4th, 6th, 8th and 12th weeks after V2
as compared to the last 7 days before V0 and V2.
4. Total number of TN attacks in comparison to
baseline and V1.
5. Tolerability and safety: adverse events, abnormal
neurological and clinical findings assessed in
V1–4, Clinical Global Impression (CGI) assessed
in V1–4 [39].
6. Rescue analgesic medication needed as compared to
placebo and run-in phase.
7. Number of days with TN attacks after V2.
8. Therapy response (reduction of TN attacks per
day ≥ 30 %) in 4th, 8th and 12th therapy weeks
as compared to baseline and in 16th, 20th and
24th weeks as compared to baseline and 12th
therapy week
9. Quality of life/impairment in everyday life assessed in
V0, V2 and V4 by a) 12-item short form questionnaire
(SF-12), b) Headache Impact Test (HIT-6), c) Allge-




Medical prophylactic therapy of TN can be administered
as long as dosages remain consistent from 4 weeks prior
to the beginning and throughout the course of the study.
The following drugs are permitted, with the respective
maximum dosages and under the surveillance of po-
tential side effects: CBZ, OXC, baclofen, phenytoin,
gabapentin, lamotrigine, levetiracetam, pregabalin, topir-
amate und valproic acid.
Opioids and tricyclic antidepressants (e.g. amitriptyl-
ine) can potentially alter TN attack frequency and are,
therefore, only permitted when the dosage remains un-
changed from 4 weeks prior to the beginning of the
study and throughout the course of the study.
Rescue pain medication
The following analgesic substances and their maximal daily
doses are permitted throughout the course of the study,
their use should be documented in the patient’s diary.
Ibuprofen max. 800 mg/d
Acetylsalicylic acid max. 1000 mg/d
Indomethacin max. 50 mg/d
Diclofenac max. 50 mg/d
Naproxen max. 250 mg/d
Fig. 1 Flow chart of Botulinum neurotoxin type A in the treatment of classical Trigeminal Neuralgia (BoTN)
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Paracetamol max. 1000 mg/d
Metamizol max. 2000 mg/d
Mixed analgesics, i.e. Thomapyrin (acetylsalicylic acid
250 mg, paracetamol 200 mg and caffeine 50 mg) 2
tablets per day.
Visit scheme
Screening visit (“visit −1”)
In the screening visit a standardized interview is per-
formed: eligibility is assessed and informed consent ob-
tained. Subjective burden will be evaluated with three
standardized questionnaires addressing quality of life
(SF-12), depression (ADS) and headache severity head-
ache (HIT-6).
Medical and neurological examinations are performed
and blood samples are obtained in order to screen for
acute infections and disorders of hemostasis. A pain
diary is handed out for the assessment of the patient`s
baseline TN attack frequency.
Visit 0 (baseline)
This visit is scheduled 8 days after the screening visit.
Eligible study patients with an average of three or more
TN paroxysms per day during baseline phase are treated
with BT-A injections in a single blinded manner (for fur-
ther details see “blinding process” below).
Visit 1
Visit 1 is performed between 28 and 31 days after V0 and
consists of a standardized, interview as well as medical and
neurological examination. ADS, HIT-6 and SF-12 scores
are reassessed and adverse events documented. Patients
with insufficient therapy response finish the study early.
Visit 2
Visit 2 (between 84 and 87 days after V0) consists of the
second, this time double blind, placebo controlled, inter-
vention and in addition to that neurological and medical
examination and assessment of adverse events and ADS,
HIT-6 and SF-12 scores.
Visit 3
V3 is comparable to V1 and is scheduled 28–31 days after
V2. A standardized interview, medical and neurological
examination, assessment of ADS, HIT-6 and SF-12 scores as
well as documentation of all adverse events are performed.
Visit 4
V4 (between 84 and 87 days after V2) is the final visit
and includes neurological and medical examination and
assessment of adverse events (including lab work) and
ADS, HIT-6 and SF-12 scores. Responders to BT-A ther-
apy are offered continuing BT-A injections as off-label-
treatment, if health care providers offer reimbursement
of the therapy costs.
Laboratory testing
Laboratory testing will be performed in V1 including:
alanine transaminase, aspartate transaminase, gamma-
glutamyl transpeptidase, hemoglobin, white blood cell
count, platelet count, creatinine, c-reactive peptide, pro-
thrombin time/international normalized ratio (INR), and
partial thromboplastin time.
Additional neurophysiological testing
The analgesic mechanisms of BT-A on the trigeminal
nociceptive system will be further examined by neuro-
physiological tests: before visits V0–V4 nociceptive blink
reflex and pain-related evoked potentials will be re-
corded using a concentric electrode which generates a
series of short painful stimuli over nerve branch V1 of
the affected side. This method is established in the testing
of trigeminal nociceptive fiber function and the evaluation
of supraspinal trigeminal pain processing and central fa-
cilitation. It has been used in studies of TN as well as
other headache disorders and has no known serious side
effects [43–46]. For more information on recording tech-
nique, background information and informative value
please see reference [47, 48] (Fig. 3).
Randomization/blinding process
Before participation in the trial patients are informed
that in the two scheduled interventions they will receive
at least once a verum injection with BT-A.
The first intervention in V1 is single blind: BT-A is
dissolved in 0.9 % saline and filled in 1- ml injection sy-
ringes. This process is not visible to the patient.
Fig. 2 Injection scheme of Botulinum neurotoxin type A in the
treatment of classical Trigeminal Neuralgia (BoTN). Nerve exits of the
affected trigeminal branches will be palpated and identified. Five units
of BT-A are injected at three sites per branch 1.5 cm apart. Injection
sites of the first trigeminal branch are kept 1.5 cm above the eyebrows
in order to prevent ptosis
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The second intervention in V2 is double blind and,
therefore, the process of reconstitution will be performed
in the pharmacy of the University Hospital Essen:
 Prior to the intervention (<24 hours) a pharmacist,
who is not further involved in the conduction and/or
analysis of the study dissolves either BT-A in 1 ml of
0.9 % saline or fills the 1-ml injection syringes solely
with 0.9 % saline. This process is not visible either to
the patient or to any member of the study group
 The allocation to the verum or placebo group is done
in a pseudorandomized manner: a randomization list
assigns screening numbers of patients to either the
placebo or verum group. This list is only accessible to
the pharmacist who is responsible for the
reconstitution of BT-A. The screening number is
handed out to the pharmacy prior to the intervention
by a member of the study group.
Eligibility
Inclusion criteria
 Men and women age 18 years or more, of legal
competence and with sufficient knowledge of
written and spoken German, capable of presenting
themselves to regular visits
 Diagnosis of classic TN as defined in the
International Classification of Headache Disorders,
third edition (ICHD-3 beta)
 Baseline TN frequency of at least 3 paroxysms per
day for < 15 days/month
 At least 1 treatment attempt with CBZ and
either insufficient therapy response under a daily
dosage of at least 600 mg/d or intolerable side
effects
 Stable dosage of concomitant TN drug therapy
in the last 4 weeks before participation in the
study
 Stable dosage of concomitant drug therapy with
potential influence on TN frequency and pain
intensity (tricyclic antidepressants, opioids).
Exclusion criteria
 Symptomatic painful trigeminopathies/symptomatic
TN
 History of trigeminoautonomic headache
syndromes:
Fig. 3 Nociceptive blink reflex and pain- related evoked potentials
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Short-lasting Unilateral Neuralgiform headache
with Conjunctival injection and Tearing (SUNCT)
Short-lasting Unilateral Neuralgiform headache




 Known sensitivity/intolerance to BT-A
 Contraindications against Botox® according to
summary of product characteristics:
www.allergan.com
 Local inflammation at injection site
 Impaired hemostasis, anticoagulatory medication
 Known motor neuron or neuropathic disease
 Impairment of neuromuscular transmission
 History of dysphagia
 Corneal ulceration
 Severe allergic diathesis
 Terminal or psychiatric comorbidities
 Pregnancy
 Nursing period
 History of alcoholism/substance abuse
Excluded therapies and medications
Concomitant medication/non-medical treatment will be
documented. The following substances which can potentially
alter the efficacy of BT-A cannot be taken during the study
and need to be stopped at least 10 days prior to the begin-
ning of the study:
 Spectinomycin
 Aminoglycosides
 Substances blocking neuromuscular transmission,
e.g. non-depolarizing muscle relaxants, succinylcho-
line, dantrolene
Anticoagulatory drugs cannot be taken during the
study and need to be stopped at least 10 days prior to
the beginning of the study:
 Oral anticoagulants (dabigatran, rivaroxaban,
abixaban, coumarin-derivatives)
 Heparin and low molecular weight heparins in
effective anticoagulatory dosage
Assessment of representativeness
All patients screened for BoTN will be registered and
documented (date, age, sex, reason for exclusion) in
order to assess representativeness of the included patient
group.
Patients can always withdraw their consent to partici-
pate in the study without stating a reason.
Statistical analysis and sample size considerations
Definition of study populations
Safety assessment group
Every patient who received BT-A at least once will be in-
cluded in the safety assessment group. Patients who quit
the study early should still participate in the following
visits for safety assessment.
ITT population
The intention-to-treat-analysis (ITT) population will
consist of patients who have received study medication
once, but analyses will be performed with respect to
randomization allocation.
Randomized ITT population
All responders in the first single blinded part of the trial
will be included in the analysis of the randomized ITT
population.
PP population
The per-protocol (PP) population excludes patients with
protocol violations such as violation of inclusion/exclu-
sion criteria or illegitimate changes in concomitant
medication. Prior to unblinding the sponsor and the
responsible biometrician will determine whether the pa-
tient will be allocated to PP-analysis or ITT-analysis.
Efficacy
The primary endpoint in the efficacy assessment is the
average number of TN paroxysms within the fourth
week after double blind intervention in V2 (the last 4
days before V3). The confirmatory analysis of the
primary endpoint will be the comparison of the verum
(μBotox) and placebo group (μplacebo) with the following,
formal hypotheses:
H0 : μBotox ¼ μplacebo
H1 : μBotox≠μplacebo
The confirmatory testing will be performed with the
randomized ITT population.
Sensitivity analysis
Due to the small sample size further subgroup analysis
will be limited to separate assessment of the female and
male patient population.
Secondary endpoints will undergo explorative and de-
scriptive analysis – e.g. in the ITT and PP populations.
Details will be described in a statistical analysis plan.
Safety
All patients of the safety assessment group will take part
in the analysis of tolerability and safety. The assessment
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is part of the screening and all follow-up visits and con-
tains: medical and neurological examination and grading
of tolerability on a four-point scale. Adverse events and
suspected adverse effects will be separately documented
in the Case Report Form (CRF) including duration, se-
verity, their possible relation to the study medication,
medical measures taken and its outcome. Severe adverse
events will be published as single case reports.
Sample size and power
Primary endpoint is the average number of TN parox-
ysms within the fourth week after double blind interven-
tion. The effect size is estimated at 1.2 and the sample
size is calculated by using the Wilcoxon-Mann-Whitney
test (software used is G® Power Version 3.1.9.2.).
With α = 0.05 and β-error = 0.80 the expected sample
size per group is n = 14, respectively n = 17 considering
the expected drop-out rate of 20 %.
Overall a total of 34 recruited patients is expected to
be necessary and at least 28 patients need to enter the
randomized double blind arm of the trial. Further pa-
tients will be recruited if there are more non-responders
to treatment as estimated.
Quality assurance/monitoring
Due to the small size of this study the sponsor disclaims
external monitoring. The sponsor is held responsible for
the surveillance of this study and monitoring activity
(e.g. source data verification, assessment of protocol vio-
lations) will be performed by a person (monitor) with
the adequate qualification who is not further involved in
the execution and analysis of this trial. All patients will
be monitored.
Every member of the study group has received the ne-
cessary training in the conduction of this specific trial
and is adequately qualified in accordance with Good
Clinical Practice (GCP).
Informed consent, ethics, data safety monitoring board
Informed consent
A written informed consent must be obtained from all
patients before the trial. This will also be documented in
the clinical file. Informed consent includes general char-
acteristics of the study, alternative treatment options,
potential risks and benefits from the study, as well as the
right to withdraw consent at any given time.
Ethics/legal approval
All procedures of this study are in accordance to the
German legal regulations of the Medicinal Products Act
(AMG), the Declaration of Helsinki and the current version
of the International Conference on Harmonization-GCP
(ICH-GCP) guidelines. The conduct of this trial, as well as
its study protocol have been approved by the responsible
ethics committee of the university of Duisburg-Essen,
as well as by the responsible surveilling authorities
Bundesinstitut für Arzneimittel und Medizinprodukte,
the Federal Institute for Drugs and Medical Devices
(BfARM).
List of the responsible ethics committees
The Ethics Committee of the Medical Faculty of the
University of Duisburg-Essen, see also Additional file 1
(“List of the responsible ethics committee and surveilling
authorities”) for further details.
Discussion
BoTN investigates the efficacy and safety of local BT-A
injections in the treatment of otherwise therapy-
refractory TN in addition to concomitant standard drug
treatment. All eligible patients will be first treated with
verum in a single blinded manner. Responders will be
randomized 1:1 to a second intervention that is double
blind, placebo controlled (randomized withdrawal
design).
Local BT-A injections may prove to be a potentially
safe and efficient additional treatment option for severe
cases of TN. Additional neurophysiological testing may
provide further insight into the antinociceptive mecha-
nisms of BT-A.
Trial status
Patient recruitment has begun and is still ongoing.
Consent
Written informed consent was obtained from the pa-
tient(s) for publication of this manuscript and accom-
panying images. A copy of the written consent is
available for review by the editor-in-chief of this journal.
Additional file
Additional file 1: List of the responsible ethics committee and
surveilling authority. List includes name and address of the responsible
ethics committee and the responsible federal surveilling authority.
(DOCX 15 kb)
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